Successful Inaugural Trading Session on ARTEX Stock Exchange

PR REF: ARTX/01 2024

Vaduz, Saturday 09 March 2024

ARTEX MTF, the exchange for art shares trading, is pleased to announce the successful first trading session. This first short session marked a historical shift in art investment and the financial market.

Shares opened at EUR 92.20 and closed at EUR 95.00, representing an increase of 3.04%.The successful trading session underscores the potential for art shares to become an important asset class, offering investors a new avenue for diversification. With the completion of this first session, the journey towards art democratisation is firmly underway.

* * *
About ARTEX MTF

ARTEX operates a secure and liquid art shares exchange, regulated and supervised by the Financial Markets Authority of Liechtenstein within the European MiFID II legislative framework. Providing easy access to a traditionally exclusive fine art market, ARTEX aims to democratise investing in artworks from the world’s greatest masters, spanning a period from the Renaissance to the twentieth century. ARTEX-listed masterpieces will be on public display, in museums and exhibitions around the world. ARTEX was co-founded in 2020 by art enthusiasts and financial markets experts H.S.H. Prince Wenceslas of Liechtenstein and Yassir Benjelloun-Touimi.

“ARTEX MTF” is a Multilateral Trading Facility operated by ARTEX MTF AG, a Company incorporated in the Principality of Liechtenstein under company number FL-0002.682.571-2 with registered offices at Wuhrstrasse 6, 9490 Vaduz, Liechtenstein. ARTEX MTF is regulated by the Financial Markets Authority under reference number 307407.

Press contacts

France and Global
Aliénor Miens | [email protected] | +33 (0)6 64 32 81 75
Bertrand Chambenois | [email protected] | +33 (0)6 11 84 34 92

Bookrunner
Zeus Capital Limited
Ben Robertson (Head of ECM)
[email protected]
125 Old Broad Street, 12th Floor, London, EC2N 1AR
www.zeuscapital.co.uk

ARTEX MTF
Please contact Aliénor Miens as indicated above.

You May Also Be Interested In

• BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
• BioSyent Schedules Q2 and H1 2026 Earnings Release for August 20, 2026
• AirJoule Technologies Announces Second Quarter 2026 Results and Provides Business Update